System and methods for the production of personalized drug products
First Claim
1. A system for producing a drug product for an individual patient, comprising:
- a computer processor configured to receive information relating to the patient and to predict, based on the received patient information, an optimal drug selection, combination drug product comprising a plurality of discrete units of a first drug and a plurality of discrete units of a second drug, and dosage for the patient; and
a drug production device, in communication with the processor, for producing the drug product based on the predicted optimal drug selection, combination drug product, and dosage, wherein the drug production device comprises;
a plurality of drug containers, each configured to hold a quantity of a drug in the form of microtablets, each microtablet containing an equal sized dose of a particular drug, each microtablet being coated so as to enable drugs of different pH to be in close locality without interaction of components of the combination drug product, and each having a unique coupling element to couple the drug container to the drug production device;
a plurality of drug dispensers, each of said drug dispensers coupled to one of said drug containers;
a supply of empty ingestible capsules;
a controller, which controls dispensing by count of said microtablets of a drug by each drug dispenser into the ingestible capsules;
a verification unit including a scanner for scanning identifying indicia provided on the drug containers and comparing the indicia to the predicted optimal drug selection and combination drug product, wherein the combination drug product comprises at least a first coated microtablet of a first drug and a second coated microtablet of a second drug, wherein the second drug is distinct from the first drug, in a closed unitary ingestible capsule package customized for the patient produced from selected dispensed drugs, wherein the patient information includes information selected from (1) at least one of the group consisting of;
weight;
age;
sex;
BSA (body surface area);
body mass index;
lean body mass, percentage body fat, metabolism;
renal function;
liver enzymes;
proteomics/biomarkers, blood chemistries, pharmacokinetics;
risk factors for disease;
partial or full genome SNP screening data;
whole or partial genome analysis;
vitamin deficiencies;
vitamin and micronutrient levels;
diet;
environmental, toxin or other allergy history;
the patient'"'"'s medical history;
diagnostic information;
exercise activity;
sleep activities;
tissue expression profiling;
hormonal cycles, biomarker information;
radiologic/imaging information, demographic information;
monthly reproductive cycle;
geolocation, social network, consumer information, habits, physiologic data, electroencephalogram (EEG) recordings, behavioral history, geographic history, exposures or potential exposures to toxins and other environmental factors including exposure to radiation, compliance history and personality testing from body measurement devices, and (2) at least one of the group consisting of current medications;
other medications/supplements;
history of prior side effects to one or more medications;
analysis of pharmacogenomic and/or pharmacogenetic profile;
drug-drug interaction information;
drug-diet interaction information; and
drug allergies and/or sensitivities; and
a conveyor for moving an ingestible capsule to successive drug dispensers, wherein a determined quantity of each drug is dispensed into the ingestible capsule from each drug dispenser.
0 Assignments
0 Petitions
Accused Products
Abstract
A system and method for determining an optimal combination drug product for a particular patient includes a processor that receives patient information and determines an optimal combination drug product based on the received information. A system which can provide information regarding predicted events or pathologies based on received patient information and guidance on subsequent steps to ameliorate, treat or intervent. A drug production device includes a plurality of drug containers, each of which are coupled to a drug dispensing channel. A controller controls the dispensing of drug through each channel, and a combination drug product is produced from the dispensed drugs. A combination drug product includes a plurality of discrete units of a first drug, and a plurality of discrete units of a second drug. A transdermal patch includes a plurality of drug compartments, each containing a quantity of drug product, and a controller for controlling the release of drugs from each compartment. Feedback loop elements can enable iterations to optimized personalized doses.
59 Citations
36 Claims
-
1. A system for producing a drug product for an individual patient, comprising:
-
a computer processor configured to receive information relating to the patient and to predict, based on the received patient information, an optimal drug selection, combination drug product comprising a plurality of discrete units of a first drug and a plurality of discrete units of a second drug, and dosage for the patient; and a drug production device, in communication with the processor, for producing the drug product based on the predicted optimal drug selection, combination drug product, and dosage, wherein the drug production device comprises; a plurality of drug containers, each configured to hold a quantity of a drug in the form of microtablets, each microtablet containing an equal sized dose of a particular drug, each microtablet being coated so as to enable drugs of different pH to be in close locality without interaction of components of the combination drug product, and each having a unique coupling element to couple the drug container to the drug production device; a plurality of drug dispensers, each of said drug dispensers coupled to one of said drug containers; a supply of empty ingestible capsules; a controller, which controls dispensing by count of said microtablets of a drug by each drug dispenser into the ingestible capsules; a verification unit including a scanner for scanning identifying indicia provided on the drug containers and comparing the indicia to the predicted optimal drug selection and combination drug product, wherein the combination drug product comprises at least a first coated microtablet of a first drug and a second coated microtablet of a second drug, wherein the second drug is distinct from the first drug, in a closed unitary ingestible capsule package customized for the patient produced from selected dispensed drugs, wherein the patient information includes information selected from (1) at least one of the group consisting of;
weight;
age;
sex;
BSA (body surface area);
body mass index;
lean body mass, percentage body fat, metabolism;
renal function;
liver enzymes;
proteomics/biomarkers, blood chemistries, pharmacokinetics;
risk factors for disease;
partial or full genome SNP screening data;
whole or partial genome analysis;
vitamin deficiencies;
vitamin and micronutrient levels;
diet;
environmental, toxin or other allergy history;
the patient'"'"'s medical history;
diagnostic information;
exercise activity;
sleep activities;
tissue expression profiling;
hormonal cycles, biomarker information;
radiologic/imaging information, demographic information;
monthly reproductive cycle;
geolocation, social network, consumer information, habits, physiologic data, electroencephalogram (EEG) recordings, behavioral history, geographic history, exposures or potential exposures to toxins and other environmental factors including exposure to radiation, compliance history and personality testing from body measurement devices, and (2) at least one of the group consisting of current medications;
other medications/supplements;
history of prior side effects to one or more medications;
analysis of pharmacogenomic and/or pharmacogenetic profile;
drug-drug interaction information;
drug-diet interaction information; and
drug allergies and/or sensitivities; anda conveyor for moving an ingestible capsule to successive drug dispensers, wherein a determined quantity of each drug is dispensed into the ingestible capsule from each drug dispenser. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
-
-
16. A method for producing a custom, optimal combination drug product for an individual patient, comprising:
-
receiving, by a processor, information relating to the patient; predicting, by the processor, an optimal drug selection, combination drug product comprising a plurality of discrete units of a first drug and a plurality of discrete units of a second drug, and dosage for the patient, based on said received patient information; outputting the predicted optimal drug selection, combination drug product, and dosage for the particular patient to a drug production device which comprises; a plurality of drug containers, each configured to hold a quantity of a drug in the form of microtablets, each microtablet containing an equal sized dose of a particular drug, each microtablet being coated so as to enable drugs of different pH to be in close locality without interaction of components of the combination drug product, and each drug container having a unique coupling element to couple the drug container to the drug production device; a plurality of drug dispensers, each of said drug dispensers coupled to one of said drug containers; a supply of empty ingestible capsules; a controller, which controls dispensing by count of said microtablets of a selected drug or drugs by each drug dispenser into the ingestible capsules; a conveyor for moving an ingestible capsule to successive drug dispensers, wherein a determined quantity of each drug is dispensed into the ingestible capsule from each drug dispenser; and a verification unit including a scanner for scanning identifying indicia provided on the drug containers and comparing the indicia to the predicted optimal drug selection and combination drug product, dispensing a controlled amount of selected drugs comprising at least a first coated microtablet of a first drug and a second coated microtablet of a second drug, wherein the second drug is distinct from the first drug, via the controller, into an empty ingestible capsule, closing the capsule using the drug production device to produce a closed unitary ingestible capsule package comprising the combination drug product customized for said individual patient, wherein the patient information includes information selected from (1) at least one of the group consisting of;
weight;
age;
sex;
BSA (body surface area);
body mass index;
lean body mass, percentage body fat, metabolism;
renal function;
liver enzymes;
proteomics/biomarkers, blood chemistries, pharmacokinetics;
risk factors for disease;
partial or full genome SNP screening data;
whole or partial genome analysis;
vitamin deficiencies;
vitamin and micronutrient levels;
diet;
environmental, toxin or other allergy history;
the patient'"'"'s medical history;
diagnostic information;
exercise activity;
sleep activities;
tissue expression profiling;
hormonal cycles, biomarker information;
radiologic/imaging information, demographic information;
monthly reproductive cycle;
geolocation, social network, consumer information, habits, physiologic data, electroencephalogram (EEG) recordings, behavioral history, geographic history, exposures or potential exposures to toxins and other environmental factors including exposure to radiation, compliance history and personality testing from body measurement devices, and (2) at least one of the group consisting of current medications;
other medications/supplements;
history of prior side effects to one or more medications;
analysis of pharmacogenomic and/or pharmacogenetic profile;
drug-drug interaction information;
drug-diet interaction information; and
drug allergies and/or sensitivities. - View Dependent Claims (17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
-
-
27. A non-transitory computer readable medium containing instructions to cause a computing device to perform a method comprising:
-
receiving, by a processor, information relating to a patient; predicting, by the processor, an optimal drug selection, combination drug product comprising a plurality of discrete units of a first drug and a plurality of discrete units of a second drug, and dosage for said patient, based on said received patient information; outputting the predicted optimal drug selection, combination drug product, and dosage for the particular patient to a drug production device which comprises; a plurality of drug containers, each configured to hold a quantity of a drug in the form of microtablets containing equally sized doses of a particular drug, each microtablet being coated so as to enable drugs of different pH to be in close locality without interaction of components of the combination drug product, and each drug container having a unique coupling element to couple the drug container to the drug production device; a plurality of drug dispensers, each of said drug dispensers coupled to one of said drug containers; a supply of empty ingestible capsules; a controller, which controls dispensing by count of said microtablets of a selected drug or drugs by each drug dispenser into the ingestible capsules; a conveyor for moving an ingestible capsule to successive drug dispensers, wherein a determined quantity of each drug is dispensed into the ingestible capsule from each drug dispenser, and a verification unit including a scanner for scanning identifying indicia provided on the drug containers and comparing the indicia to the predicted optimal drug selection and combination drug product, dispensing a controlled amount of selected drugs comprising at least a first coated microtablet of a first drug and a second coated microtablet of a second drug, wherein the second drug is distinct from the first drug, via the controller, into an unfilled ingestible capsule, and closing the capsule using the drug production device to produce a closed unitary ingestible capsule package comprising the combination drug product customized for said individual patient, wherein the patient information includes information selected from (1) at least one of the group consisting of;
weight;
age;
sex;
BSA (body surface area);
body mass index;
lean body mass, percentage body fat, metabolism;
renal function;
liver enzymes;
proteomics/biomarkers, blood chemistries, pharmacokinetics;
risk factors for disease;
partial or full genome SNP screening data;
whole or partial genome analysis;
vitamin deficiencies;
vitamin and micronutrient levels;
diet;
environmental, toxin or other allergy history;
the patient'"'"'s medical history;
diagnostic information;
exercise activity;
sleep activities;
tissue expression profiling;
hormonal cycles, biomarker information;
radiologic/imaging information, demographic information;
monthly reproductive cycle;
geolocation, social network, consumer information, habits, physiologic data, electroencephalogram (EEG) recordings, behavioral history, geographic history, exposures or potential exposures to toxins and other environmental factors including exposure to radiation, compliance history and personality testing from body measurement devices, and (2) at least one of the group consisting of current medications;
other medications/supplements;
history of prior side effects to one or more medications;
analysis of pharmacogenomic and/or pharmacogenetic profile;
drug-drug interaction information;
drug-diet interaction information; and
drug allergies and/or sensitivities. - View Dependent Claims (28, 29, 30, 31, 32, 33, 34, 35, 36)
-
Specification